• Lonza Reports 21.7% Sales Growth for 2025, Boosts Dividend and Issues Strong 2026 Outlook
BASEL, Switzerland – Lonza Group reported on January 28, 2026, that its full-year 2025 sales reached CHF 6.5 billion, a 21.7% increase at constant exchange rates.
The healthcare manufacturer also announced a proposed 25% dividend increase and projected continued growth for 2026.
What is new?
Lonza announced its full-year 2025 financial results, delivering sales of CHF 6.5 billion and a CORE EBITDA of CHF 2.1 billion, resulting in a margin of 31.6%. The performance outperformed the company’s upgraded outlook for the year. The Board of Directors will propose a dividend of CHF 5.00 per share, an increase of 25% compared to the prior year. The results were supported by maturing growth projects, operational execution, and a higher than expected contribution from its Vacaville site.
Financial Highlights
The company’s performance varied across its business platforms. The Integrated Biologics division reported strong sales growth of 32.2% at constant exchange rates, driven by the Vacaville site acquisition which generated approximately CHF 0.6 billion in sales. The Advanced Synthesis division saw exceptionally strong growth of 22.4%, supported by the ramp-up of new projects. In contrast, the Specialized Modalities platform reported a sales decline of 3.0%, impacted by a softer performance in Cell & Gene and phasing in Microbial, though it showed improving trends in the second half of the year.
The Capsules & Health Ingredients (CHI) business, which is reported as a Discontinued Operation, saw sales growth of 3.9% at constant exchange rates and an improved CORE EBITDA margin of 25.9%. Lonza has continued to advance the carve-out and exit process for the CHI business as planned.
Update: Wolfgang Wienand Becomes Lonza Ceo, Succeeding Albert M. Baehny
Strategic Progress
In 2025, Lonza successfully implemented a new “One Lonza” operating model on April 1, designed to streamline operations through three aligned business platforms. The company also completed the integration of its large-scale Vacaville, California, facility into its global manufacturing network. The site secured a fifth significant commercial contract and passed its first US FDA audit under Lonza ownership. The company invested CHF 1.3 billion in capital expenditures during the year to execute its organic investment program and enable future growth.
2026 Outlook
For 2026, Lonza anticipates continued strong performance, forecasting sales growth of 11-12% at constant exchange rates. The company also expects its CORE EBITDA margin to expand further, reaching a level above 32%. A foreign exchange headwind of approximately -2.0% on sales is anticipated, mainly from the full-year effect of the weakening of the US Dollar in 2025. The company stated it expects no material financial impact from currently published US trade and tariff policies but will continue to monitor the situation.
About this company
Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, its global community of approximately 20,000 colleagues helps pharmaceutical and biotech companies bring their treatments to market. The company supports its customers with a combination of technological insight, world-class manufacturing, scientific expertise, and process excellence. Lonza is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange.
Read more
Update: Kruk 2024 Total Recoveries: Pln 2,6M, +14% Y/Y, Mostly From Abroad